Neurocrine Biosciences and Catalyst Pharmaceutical are being considered for value stock investment.
2 reports, 1 independent
Updated Jul 28
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Neurocrine Biosciences and Catalyst Pharmaceutical are being considered for value stock investment.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Morgan Stanley raised its price target for Neurocrine Biosciences stock, a company that develops treatments for Huntington's chorea.Sub-event
Neurocrine Biosciences and Catalyst Pharmaceutical are being considered for value stock investment.1 source
- CPRX received better earnings estimate revisions.
Keep exploring
The entities involved
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ZacksCPRX vs. NBIX: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences
- Unknown outlet